103.87MMarket Cap
0.81P/E TTM
Key Figures
3.280Open
3.280High
643.00KVolume
0.81P/E TTM
4.92P/E Dynamic
--Dividend TTM
1.94%Turnover Ratio
3.290Prev. Close
3.080Low
1.50MTurnover
LossP/E Static
0.64P/B
0.00%Div Yield TTM
48.21%ROA
4.53052wk High
1.43Volume Ratio
-55.89MNet Profit
33.19MShares
3.8490EPS TTM
1.22Beta
129.25%ROE
1.70052wk Low
6.07%Amplitude
54.21%Gross Margin
103.87MMarket Cap
2.72Reward/Risk
4.24%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Fortress Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fortress Biotech Inc's Score
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Fortress Biotech Inc Highlights
StrengthsRisks
Fortress Biotech Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
Fortress Biotech Inc Info
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Ticker SymbolFBIO
CompanyFortress Biotech Inc
CEORosenwald (Lindsay A)
Websitehttps://www.fortressbiotech.com/
Shareholders
FAQs
What is the current price of Fortress Biotech Inc (FBIO)?
The current price of Fortress Biotech Inc (FBIO) is 3.13.
What is the symbol of Fortress Biotech Inc?
The ticker symbol of Fortress Biotech Inc is FBIO.
What is the 52-week high of Fortress Biotech Inc?
The 52-week high of Fortress Biotech Inc is 4.53.
What is the 52-week low of Fortress Biotech Inc?
The 52-week low of Fortress Biotech Inc is 1.70.
What is the market capitalization of Fortress Biotech Inc?
The market capitalization of Fortress Biotech Inc is 103.87M.
Is Fortress Biotech Inc (FBIO) currently rated as Buy, Hold, or Sell?
According to analysts, Fortress Biotech Inc (FBIO) has an overall rating of Buy, with a price target of 11.00.
What is the Earnings Per Share (EPS TTM) of Fortress Biotech Inc (FBIO)?
The Earnings Per Share (EPS TTM) of Fortress Biotech Inc (FBIO) is -0.07.